• Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

      Motzer, R; Hutson, T; Cella, D; Reeves, J; Hawkins, Robert E; Guo, J; Nathan, P; Staehler, M; de Souza, P; Merchan, J; et al. (2013-08-22)
      Pazopanib and sunitinib provided a progression-free survival benefit, as compared with placebo or interferon, in previous phase 3 studies involving patients with metastatic renal-cell carcinoma. This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy.